Selatogrel, a Reversible P2Y12 Receptor Antagonist, Has Reduced Off-target Interference with Haemostatic Factors in a Mouse Thrombosis Model

Selatogrel is a reversible antagonist of the P2Y12 receptor. In rat thrombosis/haemostasis models, selatogrel was associated with lower blood loss than clopidogrel or ticagrelor at equivalent anti-thrombotic effect.

Source: Thrombosis Research - February 6, 2021 Category: Hematology Authors: Markus A. Riederer, Lydie Crescence, Roxane Darbousset, Eva Caroff, Francis Hubler, Laurence Panicot-Dubois, Christophe Dubois Source Type: research